actin binding raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-02 and is reviewed periodically as new material appears.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
=== Mechanisms of drug-induced cholestasis === Drugs may induce cholestasis by interfering with 1) hepatic transporters, 2) bile canaliculi dynamics, and/or 3) cell structure and protein localization. Hepatic transporters are essential for maintaining enterohepatic bile flow and bile acid homeostasis. Therefore, their direct inhibition by certain drugs may lead to cholestasis. Relevant transporters implicated include BSEP, MDR3, MRP2-4, and NTCP. Cholestasis can result from competitive inhibition of BSEP by several drugs, including cyclosporine A, rifampicin, nefazodone, glibenclamide, troglitazone, and bosentan. BSEP is the main transporter in hepatocytes responsible for exporting bile salts across the apical membrane into bile canaliculi. Therefore, inhibiting BSEP should cause cytotoxic bile salts to accumulate in hepatocytes, leading to liver injury and impaired bile flow. Indeed, there is a strong association between BSEP inhibition and cholestasis in humans, and BSEP inhibitors are shown to induce cholestasis in vitro. However, hepatocytes have safety mechanisms that can compensate for impaired canalicular bile efflux. In response to cholestasis, MRP3 and MRP4 on the basolateral membrane are upregulated to allow efflux of accumulated bile salts into portal blood. Similarly, MRP2 can accommodate additional bile flow across the apical membrane in cholestatic conditions. These compensatory mechanisms explain why some BSEP inhibitors do not cause cholestasis.
=== Conformation change mechanism pathway (without proteolysis) === αVβ6 integrin was the first integrin to be identified as TGF-β1 activator. LAPs contain an RGD motif which is recognized by vast majority of αV containing integrins, and αVβ6 integrin can activate TGF-β1 by binding to the RGD motif present in LAP-β1 and LAP-β3. Upon binding, it induces adhesion-mediated cell forces that are translated into biochemical signals which can lead to liberation/activation of TGFb from its latent complex. This pathway has been demonstrated for activation of TGF-β in epithelial cells and does not associate MMPs.
The need for an international standard for chemistry was first addressed in 1860 by a committee headed by German scientist Friedrich August Kekulé von Stradonitz. This committee was the first international conference to create an international naming system for organic compounds. The ideas that were formulated at that conference evolved into the official IUPAC nomenclature of organic chemistry. IUPAC is a legacy of this meeting, making it one of the most important historical international collaborations of chemistry societies. IUPAC as such was established in 1919.Since this time, IUPAC has been the official organization with the responsibility of updating and maintaining official organic nomenclature. One notable country excluded from early IUPAC was Germany. Germany's exclusion was a result of prejudice towards it by the Allied powers after World War I. Germany was finally admitted into IUPAC in 1929. However, Nazi Germany was removed from IUPAC during World War II. At this time, IUPAC was affiliated with the Allied powers, but had little involvement with the war effort itself. East and West Germany were only readmitted to IUPAC in 1973. Since World War II, IUPAC has focused on standardizing nomenclature and methods in science. In 2016, IUPAC denounced the use of chlorine as a chemical weapon. In a letter to Ahmet Üzümcü, director of the Organisation for the Prohibition of Chemical Weapons (OPCW), the organization pointed out their concerns in regards to chlorine weapon usage in the Syrian civil war and other places .
The following is a list of fentanyl analogues (sometimes referred to as fentalogs), and includes both compounds developed by pharmaceutical companies for legitimate medical use, and those which have been sold as designer drugs. The latter have been reported to national drug control agencies such as the DEA, and some to transnational agencies such as the EMCDDA and UNODC. This is not a comprehensive or exhaustive list of fentanyl analogues, as more than 1400 compounds from this family have been described in the scientific and patent literature. However, this list does include many notable compounds that have reached late-stage human clinical trials, and compounds which have been sold as designer drugs, as well as representative examples of significant structural variations reported in the scientific and patent literature. The structural variations among fentanyl analogues can impart profound pharmacological differences between each other, especially regarding potency and efficacy. In the United States, the Drug Enforcement Administration (DEA) placed the class of "Fentanyl-Related Substances" on the list of Schedule I drugs in 2018, making it illegal to manufacture, distribute, or possess fentanyl analogs, with very broad terminology being used in its scheduling. Regarding the temporary control of fentanyl-related substances, Schedule I was extended through December 31, 2024 by Public Law 117-328.
Sources: en.wikipedia.org
==== 1600–1699 ==== Department of Transport (Fees) (Amendment) Order 1993 (S.I. 1993/1601) Motor Vehicles (Driving Licences) (Amendment) Regulations 1993 (S.I. 1993/1602) Motor Vehicles (Driving Licences) (Large Goods and Passenger-Carrying Vehicles) (Amendment) Regulations 1993 (S.I. 1993/1603) Education (School and Placing Information) (Scotland) Amendment, Etc., Regulations 1993 (S.I. 1993/1604) Education (Provision of Information as to Schools) (Scotland) Regulations 1993 (S.I. 1993/1605) Food Protection (Emergency Prohibitions) (Paralytic Shellfish Poisoning) (No.7) Order 1993 (S.I. 1993/1606) Swanage Light Railway (Extension) Order 1993 (S.I. 1993/1607) Council Tax Limitation (Wales) (Maximum Amount) Order 1993 (S.I. 1993/1608) Further Education (Prescription of Different Date for Property Agreements) (Scotland) Order 1993 (S.I. 1993/1614) Health Boards (Membership and Procedure) (No. 2) Amendment Regulations 1993 (S.I. 1993/1615) Education (Student Loans) (Amendment) Regulations 1993 (S.I. 1993/1620) Community Action (Miscellaneous Provisions) Order 1993 (S.I. 1993/1621) Air Navigation (General) Regulations 1993 (S.I. 1993/1622) Debts of Overseas Governments (Determination of Relevant Percentage) (Amendment) Regulations 1993 (S.I. 1993/1623) Charities (Exemption from Accounting Requirements) (Scotland) Regulations 1993 (S.I. 1993/1624) Right to Purchase (Prescribed Persons) (Scotland) Order 1993 (S.I. 1993/1625) Sheep Annual Premium and Suckler Cow Premium Quotas Regulations 1993 (S.I.
== Sources == Benjamin, Denis R. (1995). Mushrooms: poisons and panaceas — a handbook for naturalists, mycologists and physicians. New York: WH Freeman and Company. ISBN 978-0-7167-2600-5. Jordan Peter; Wheeler Steven. (2001). The Ultimate Mushroom Book. London: Hermes House. ISBN 978-1-85967-092-7.
=== Ribosomal proteins with roles in signaling === Two 40S ribosomal proteins (RACK1 and RPS6 (or eS6)) have been implicated in cellular signaling: RACK1, first described as the receptor of activated protein kinase C (PKC), is an integral component of the eukaryotic ribosome and is located at the back of the head. It may link signal-transduction pathways directly to the ribosome though it also has a role in multiple translational processes that appear unrelated (reviewed in ). Ribosomal protein eS6 is located at the right foot of the 40S subunit and is phosphorylated in response to mammalian target of rapamycin (mTOR) signaling.
Sources: en.wikipedia.org
Research mainly focuses on polymers that show thermoresponsivity in aqueous solution. Promising areas of application are tissue engineering, liquid chromatography, drug delivery and bioseparation. Only a few commercial applications exist, for example, cell culture plates coated with an LCST-polymer.
==== Production ==== Angiotensin I is converted to angiotensin II (AII) through removal of two C-terminal residues by the enzyme angiotensin-converting enzyme (ACE), primarily through ACE within the lung (but also present in endothelial cells, kidney epithelial cells, and the brain). "This conversion reduces the peptide from ten amino acids (angiotensin I) to eight amino acids (angiotensin II), with the removal of the terminal His-Leu dipeptide by ACE."
=== Hobbies === Bush has been an avid reader throughout his adult life, preferring biographies and histories. During his presidency, Bush read the Bible daily, though at the end of his second term he said on television that he is "not a literalist" about Bible interpretation. Walt Harrington, a journalist, recalled seeing "books by John Fowles, F. Scott Fitzgerald, James Joyce, and Gore Vidal lying about, as well as biographies of Willa Cather and Queen Victoria" in his home when Bush was a Texas oilman. Other activities include cigar smoking and golf. Bush has also painted many paintings. One of his best-known projects is a collection of 43 paintings of immigrants, titled Out of Many, One. Another painting project was Portraits of Courage: A Commander in Chief's Tribute to America's Warrior.
== Biophysical and theoretical methods == Surface plasmon resonance (SPR) is the most common label-free technique for the measurement of biomolecular interactions. SPR instruments measure the change in the refractive index of light reflected from a metal surface (the "biosensor"). Binding of biomolecules to the other side of this surface leads to a change in the refractive index which is proportional to the mass added to the sensor surface. In a typical application, one binding partner (the "ligand", often a protein) is immobilized on the biosensor and a solution with potential binding partners (the "analyte") is channelled over this surface. The build-up of analyte over time allows to quantify on rates (kon), off rates (koff), dissociation constants (Kd) and, in some applications, active concentrations of the analyte. Several different vendors offer SPR-based devices. Best known are Biacore instruments which were the first commercially available. Dual polarisation interferometry (DPI) can be used to measure protein–protein interactions. DPI provides real-time, high-resolution measurements of molecular size, density and mass. While tagging is not necessary, one of the protein species must be immobilized on the surface of a waveguide. As well as kinetics and affinity, conformational changes during interaction can also be quantified. Static light scattering (SLS) measures changes in the Rayleigh scattering of protein complexes in solution and can characterize both weak and strong interactions without labeling or immobilization of the proteins or other biomacromolecule.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.